Biologic therapy (BRM, immunotherapy)
The FDA granted Orphan Drug designation to ADXS-HPV for treatment of stage II-IV invasive cervical cancer. Orphan drug designation is granted to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people in the US. This drug is currently in several clinical trials showing promising results. Code this drug as Other until final FDA approval is granted.
This drug should be coded